MSH2 and neoplasm: Patients with tumours showing MSH2, MSH6 or isolated PMS2 loss, or MLH1 loss/MSI with no evidence of BRAF mutation/MLH1 promoter hypermethylation, are referred for germline testing if clinically appropriate.